Zopiclone: sleep and performance studies in healthy man

Area of Science:

• Pharmacology
• Sleep Medicine
• Neuroscience

Background:

• Zopiclone is a nonbenzodiazepine hypnotic used for insomnia.
• Understanding its dose-dependent effects on sleep architecture and next-day performance is crucial for clinical application.

Purpose of the Study:

• To evaluate the effects of varying zopiclone doses (2.5, 5.0, 7.5, 10.0 mg) on sleep patterns and subsequent psychomotor performance.
• To determine the optimal zopiclone dosage for hypnotic effect with minimal residual impairment.

Main Methods:

• A double-blind, placebo-controlled study involving 6 healthy adult males (21-33 years).
• Administration of zopiclone at doses of 2.5, 5.0, 7.5, and 10.0 mg.
• Assessment of sleep parameters (stages, duration, REM sleep) and next-day performance using the Digit Symbol Substitution Test (DSST).

Main Results:

• Zopiclone doses of 5.0 and 10.0 mg reduced awake and stage 1 sleep.
• Stage 3 sleep duration increased with 7.5 mg zopiclone.
• REM sleep was delayed by 7.5 mg and reduced during the first 6 hours by 10.0 mg.
• Performance on the DSST was impaired at 9 hours post-ingestion with 7.5 and 10.0 mg zopiclone.

Conclusions:

• Doses up to 7.5 mg zopiclone appear clinically useful for insomnia.
• 7.5 mg offers a balance of hypnotic effect and minimal next-day impairment.
• 5.0 mg is recommended for individuals requiring unimpaired performance on skilled tasks the following day.